U.S. FDA approves bluebird bio’s gene therapy for a rare neurological disorder By Reuters


© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

-The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s gene therapy for the treatment of a rare neurological disorder, the company said late on Friday.

“SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys” with early, active Cerebral Adrenoleukodystrophy (CALD), the company said in a statement, saying CALD is a “devastating and fatal neurodegenerative disease.”

Bluebird said it anticipates commercial product will be available by the end of 2022 through a limited number of qualified treatment centers in the United States.

In August, the company’s beti-cel therapy secured FDA approval to treat a rare blood disorder that was priced at a record $2.8 million, the most expensive treatment to date.

CALD is caused by mutations in a gene called ABCD1 that leads to the buildup of very long-chain fatty acids in the brain and spinal cord. It typically occurs in boys between the ages of 3 and 12.

Eli-cel adds functional copies of the ABCD1 gene in a patient’s stem cells to help produce a protein required to break down the long-chain fatty acids.

The approval was largely expected after the drug received unanimous endorsement from a panel of outside advisers to the FDA in June.



Source link

Related articles

The JBL Flip 7 speaker reappears at a $50 low cost!

The JBL Cost 6 is our favourite speaker, and it's nonetheless on sale for $139.95 on Woot.com. Whereas spectacular and tremendous moveable, a few of you need one thing even simpler to hold...

SOL Methods secures Nasdaq approval as institutional giants plan billion-dollar Solana treasury

Solana (SOL) treasury firm SOL Methods secured approval to listing its frequent shares on the Nasdaq, in keeping with a Sept. 5 announcement.The corporate expects buying and selling to begin on Sept....

investingLive Americas FX information wrap: Non-farm payrolls disappoint once more

Excessive threat warning: International change buying and selling carries a excessive degree of threat that might not...

August’s Labor Knowledge Offers The Fed The Inexperienced Mild To Minimize

This text was written byComply withAbout My Writing: I'm at present targeted on revenue investing by way of both frequent shares, most popular shares, or bonds.  I'll often break free and write in...

Pulley, 645 Ventures, and Epigram Authorized be part of the Disrupt 2025 agenda

For the twentieth anniversary of TechCrunch, Disrupt 2025 (happening October 27–29 at Moscone West in San Francisco) will get actual about probably the most urgent founder questions: compensation and fairness. On the Builders Stage,...
spot_img

Latest articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

WP2Social Auto Publish Powered By : XYZScripts.com